Short answer
LIFECORE BIOMEDICAL, INC. DE (LFCR) filed its Q3 2025 10-Q quarterly report on Nov 6, 2025 for the quarter ended Sep 30, 2025.
LIFECORE BIOMEDICAL, INC. DE Q3 2025 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $31.1M, up 26% YoY from $24.7M
- Gross margin 25.0% vs 21.8% YoY
- Best segment HA manufacturing revenue $9.4M, up 107% YoY
- Cash $18.9M; $10.0M note-receivable payment and $2.5M revolving-credit repayment
- ERP launch expected Q1 2026; risks include inflation, tariffs, interest rates, suppliers, and customer demand
Risk Factors
- No risk-factors section provided in the submitted excerpt
- November 6, 2025 credit-agreement amendments indicate changed lender-consent and financing terms
- No regulatory, legal, operational, competitive, market, liquidity, maturity, currency, or concentration risks disclosed in provided text
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other LIFECORE BIOMEDICAL, INC. DE quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.